The problem of cancer-related fatigue, which affects 70% to 100% of cancer patients, has been exacerbated by the increased use of fatigue-inducing multimodal treatments and dose-dense, dose-intense protocols. In patients with metastatic disease, the prevalence of cancer-related fatigue exceeds 75%, and cancer survivors report that fatigue is a disruptive symptom months or even years after treatment ends. To address the significant problem of cancer-related fatigue, the NCCN convened a panel of experts in the field of fatigue. The Cancer-Related Fatigue Clinical Practice Guidelines synthesize the available research and clinical experience in this field and provide recommendations for patient care.
For the most recent version of the guidelines, please visit NCCN.org